drug
as of 2026-07-01d-cycloserine
D-cycloserineD-Cycloserine
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Massachusetts General Hospital
10 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Trials
10
D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions
NCT01981759Phase 4Completed
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
NCT02304432Early Phase 1Completed
Glutamate, Learning, and Working Memory
NCT02769936Phase 1Completed
Once Weekly D-cycloserine for Schizophrenia
NCT00964041Phase 4Withdrawn
D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia
NCT00963924—Completed
Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia
NCT00742079Phase 4Completed
Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia
NCT00455702Phase 4Completed
Glycine and D-Cycloserine in Schizophrenia
NCT00000372Phase 3Withdrawn
Adjunctive Treatment for Decreasing Symptoms of Schizophrenia
NCT00222235Phase 2, Phase 3Completed
Trial of D-Cycloserine in Schizophrenia
NCT00000371Phase 3Completed
KOLs & investigators
4
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
trial
trial
trial
indication
indication
indication
indication
KOL
Donald C. Goff, MD
personKOL score 8
Donald C. Goff, M.D.
personKOL score 5
William T Carpenter, MD
personKOL score 5
Deborah L. Levy, Ph.D.
personKOL score —